Repligen Corp
RGEN
查看詳細走勢圖
162.760USD
-0.580-0.36%
收盤 01/27, 16:00（美東）報價延遲15分鐘
9.16B總市值
5833.69本益比TTM
盤中分時
1分
30分
1小時
日k
週k
月k
日k
今天
-0.36%
5天
+0.46%
1月
-2.08%
6月
+33.70%
今年開始到現在
-0.67%
1年
-1.89%
查看詳細走勢圖
TradingKey Repligen Corp股票評分
單位: USD 更新時間: 2026-01-26操作建議
Repligen Corp當前公司基本面數據相對非常健康，增長潛力很大。當前估值合理，在醫療設備與耗材行業排名14/205位。機構持股佔比非常高，近一月多位分析師給出公司評級為買入。最高目標價為190.62。中期看，股價處於平穩狀態。近一個月，市場表現一般，但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間，可以做區間波段操作。
Repligen Corp評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
公司輿情
過去24小時
熱度
過冷
過熱
中性
Repligen Corp亮點
亮點風險
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.
業績轉虧
公司業績轉虧，最新年度虧損美元
估值高估
公司最新PE估值5854.48，處於3年歷史高位
機構加倉
最新機構持股62.39M股，環比增加3.41%
CI 精選加拿大股票基金持倉
明星投資者CI 精選加拿大股票基金持倉，最新持倉96.00股
分析師目標
基於
22
分析師
買入
評級
190.624
目標均價
+17.43%
漲幅空間
數據免責聲明：分析師評級與目標價由LSEG提供，僅供參考，不應當作投資建議
Repligen Corp新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
Repligen Corp簡介
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.
公司代碼RGEN
公司Repligen Corp
CEOLoeillot (Olivier)
網址https://www.repligen.com/
相關品種
-15.49%
-1.07%
+0.41%
-1.51%
-1.46%
-0.25%
-0.35%
-0.44%
+6.84%
-9.05%
-7.15%
-1.36%
-0.50%
+0.70%
-0.58%
-0.36%
+0.24%
+0.11%
+0.22%
+0.33%
